BLAINTRAVENOUS, SUBCUTANEOUSINJECTABLE1 Generic Approved
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
WEZLANA (ustekinumab-auub) by Amgen is interleukin-12 antagonists [moa]. First approved in 2023.
Drug data last refreshed 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WEZLANA (ustekinumab-auub) is a monoclonal antibody antagonist of interleukin-12, approved by the FDA on October 31, 2023. It treats a broad spectrum of immune-mediated inflammatory diseases including plaque psoriasis, Crohn's disease, ulcerative colitis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, systemic lupus erythematosus, juvenile idiopathic arthritis, atopic dermatitis, and rheumatoid arthritis. The drug works by blocking IL-12 signaling to reduce pathogenic T-cell responses across multiple autoimmune conditions.
Growth
Early-stage growth product with expanding multi-indication portfolio suggests robust commercial team expansion and high marketing investment opportunity.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
WEZLANA's growth-stage lifecycle and broad indication portfolio support nearly 1,000 linked job openings, with highest demand in clinical operations, commercial forecasting, and health economics/outcomes research. Working on this product offers exposure to multi-indication launch strategy, competitive positioning against established JAK and TNF therapies, and expansion into high-value autoimmune segments.
Clinical Scientist Director
Worked on WEZLANA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.